New Mutation Map Reveals How CTNNB1 Drives Cancer Growth and Treatment Response

Molecular Oncology /

Scientists have mapped all possible mutations in a key region of the CTNNB1 gene that controls the cancer-related protein β-catenin. Normally, this region tells the cell to break down β-catenin, but mutations allow it to build up and drive tumor growth. Using genome-editing tools in mouse stem cells, researchers tested 342 different mutations and found […]

New Mutation Map Reveals How CTNNB1 Drives Cancer Growth and Treatment Response Read More »

Tagraxofusp Shows Modest Activity and Favorable Safety in Myelofibrosis Trial

Clinical Trails /

A phase 1/2 study evaluated tagraxofusp (Elzonris), a CD123-targeted therapy, as a single-agent treatment for patients with myelofibrosis. The drug showed modest clinical benefit but was generally well tolerated, with no dose-limiting toxicities reported. These findings suggest tagraxofusp may be better suited for use in combination with other therapies rather than as a standalone treatment.

Tagraxofusp Shows Modest Activity and Favorable Safety in Myelofibrosis Trial Read More »

FDA Reviews Dato-DXd as First-Line Option for Advanced Triple-Negative Breast Cancer

Treatment /

The FDA has accepted a supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) as a first-line treatment for adults with unresectable or metastatic triple-negative breast cancer who cannot receive immunotherapy. A regulatory decision is expected in the second quarter of 2026. The application is supported by Phase 3 TROPION-Breast02 trial results showing that Dato-DXd outperformed

FDA Reviews Dato-DXd as First-Line Option for Advanced Triple-Negative Breast Cancer Read More »

Intraoperative Cisplatin Patch PRV211 Meets Safety Goal in Oral Cancer Trial

Treatment /

Privo Technologies announced that its intraoperative cisplatin patch, PRV211, met the primary safety endpoint in Arm 2 of the Phase 2/3 CLN-004 trial for patients with invasive oral cavity cancer. In the earlier phase 1/2 group of eight patients, no treatment-related serious adverse events, systemic toxicities, or dose-limiting toxicities were observed, and wound healing was

Intraoperative Cisplatin Patch PRV211 Meets Safety Goal in Oral Cancer Trial Read More »

AI Boosts Early Lung Cancer Detection and Speeds Up CT Scan Reading

Diagnostics /

New research shows that adding a deep-learning AI tool to chest CT interpretation can significantly improve radiologists’ ability to detect early-stage lung cancer while maintaining accuracy. The study found that AI assistance increased detection sensitivity by 24.3% without significantly increasing false positives. It also made readings faster, reducing the average scan interpretation time by about

AI Boosts Early Lung Cancer Detection and Speeds Up CT Scan Reading Read More »

Combination Therapy Shows Strong Survival Benefit in Advanced Pancreatic Cancer

Treatment /

Interim results from a Phase 2a trial testing a combination of atebimetinib with modified gemcitabine/nabpaclitaxel (mGnP) have shown promising survival outcomes in patients with advanced pancreatic cancer. The study reported a 64 % overall survival rate at 12 months, a significant improvement over historical benchmarks achieved with standard chemotherapy alone. This combination therapy pairs traditional chemotherapy with atebimetinib,

Combination Therapy Shows Strong Survival Benefit in Advanced Pancreatic Cancer Read More »

Four-Marker Blood Test Brings New Hope for Early Detection of Pancreatic Cancer

Diagnostics /

Researchers have developed a new blood test that could greatly improve early detection of pancreatic cancer, a disease that is often diagnosed too late to treat effectively. Scientists combined four protein markers—CA19-9, THBS2, and two newly identified markers, ANPEP and PIGR—into a single test. Using all four markers together significantly increased accuracy. The test correctly

Four-Marker Blood Test Brings New Hope for Early Detection of Pancreatic Cancer Read More »

New Strategies Aim to Break Radiation Resistance in Pancreatic Cancer

Treatment /

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poor survival rate, and most patients are not eligible for surgery. Radiation therapy has limited benefit because PDAC tumors are naturally resistant to radiation, using strategies such as low oxygen levels, strong DNA repair systems, and altered cell cycles to survive. To improve radiation effectiveness,

New Strategies Aim to Break Radiation Resistance in Pancreatic Cancer Read More »

AI and Molecular Biomarkers Redefine the Future of Lung Cancer Detection and Treatment

Diagnostics /

Lung cancer is still the leading cause of cancer-related death worldwide, largely due to smoking and environmental exposure. It mainly includes non-small cell lung cancer, which makes up most cases and has a low long-term survival rate, and small cell lung cancer, which is less common but more aggressive. Current diagnosis relies heavily on CT

AI and Molecular Biomarkers Redefine the Future of Lung Cancer Detection and Treatment Read More »

Scientists Unmask Pancreatic Cancer’s “Sugar-Coated” Defense, Opening New Path for Immunotherapy

Research Advances /

Researchers at Northwestern Medicine have discovered why pancreatic cancer often resists immunotherapy: the tumor hides behind a “sugar coating” that tells the immune system not to attack. The study, published in Cancer Research in January 2026, also describes a new antibody designed to strip away this disguise. Normally, healthy cells use a sugar called sialic acid

Scientists Unmask Pancreatic Cancer’s “Sugar-Coated” Defense, Opening New Path for Immunotherapy Read More »